UPDATED: Monday, July 14 at 9:35 a.m. ET A GSK label expansion bid for respiratory syncytial virus vaccine Arexvy is under review at the FDA.

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

AS01-adjuvanted RSV and shingles vaccines were tied to a lower dementia risk in older adults. Compared with flu vaccine recipients, those who had the AS01 RSV shot had 29% more dementia-free time ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.